These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib. Airiau K; Mahon FX; Josselin M; Jeanneteau M; Turcq B; Belloc F Exp Hematol; 2012 May; 40(5):367-78.e2. PubMed ID: 22240609 [TBL] [Abstract][Full Text] [Related]
30. Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis. O'Hare T; Eide CA; Agarwal A; Adrian LT; Zabriskie MS; Mackenzie RJ; Latocha DH; Johnson KJ; You H; Luo J; Riddle SM; Marks BD; Vogel KW; Koop DR; Apgar J; Tyner JW; Deininger MW; Druker BJ Cancer Res; 2013 Jun; 73(11):3356-70. PubMed ID: 23576564 [TBL] [Abstract][Full Text] [Related]
31. Platinum pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via DUB inhibition-dependent caspase activation and Bcr-Abl downregulation. Lan X; Zhao C; Chen X; Zhang P; Zang D; Wu J; Chen J; Long H; Yang L; Huang H; Wang X; Shi X; Liu J Cell Death Dis; 2017 Jul; 8(7):e2913. PubMed ID: 28682311 [TBL] [Abstract][Full Text] [Related]
32. A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Wagle M; Eiring AM; Wongchenko M; Lu S; Guan Y; Wang Y; Lackner M; Amler L; Hampton G; Deininger MW; O'Hare T; Yan Y Leukemia; 2016 Jul; 30(7):1493-501. PubMed ID: 27044711 [TBL] [Abstract][Full Text] [Related]
33. Integrating in vitro sensitivity and dose-response slope is predictive of clinical response to ABL kinase inhibitors in chronic myeloid leukemia. Vainstein V; Eide CA; O'Hare T; Shukron O; Druker BJ Blood; 2013 Nov; 122(19):3331-4. PubMed ID: 24062017 [TBL] [Abstract][Full Text] [Related]
34. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995 [TBL] [Abstract][Full Text] [Related]
35. Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia. Moore FR; Yang F; Press RD Methods Mol Biol; 2013; 999():25-39. PubMed ID: 23666688 [TBL] [Abstract][Full Text] [Related]
37. Metabolic alterations mediated by STAT3 promotes drug persistence in CML. Patel SB; Nemkov T; Stefanoni D; Benavides GA; Bassal MA; Crown BL; Matkins VR; Camacho V; Kuznetsova V; Hoang AT; Tenen DE; Wolock SL; Park J; Ying L; Yue Z; Chen JY; Yang H; Tenen DG; Ferrell PB; Lu R; Darley-Usmar V; D'Alessandro A; Bhatia R; Welner RS Leukemia; 2021 Dec; 35(12):3371-3382. PubMed ID: 34120146 [TBL] [Abstract][Full Text] [Related]
38. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia. Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654 [TBL] [Abstract][Full Text] [Related]
39. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function. Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074 [TBL] [Abstract][Full Text] [Related]
40. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Copland M; Pellicano F; Richmond L; Allan EK; Hamilton A; Lee FY; Weinmann R; Holyoake TL Blood; 2008 Mar; 111(5):2843-53. PubMed ID: 18156496 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]